Argenx_April_2018_586_25586

Loading viewer...

presentation

Format: PDF presentation

This presentation discusses the Phase 2 study of Efgartigimod for treating patients with Generalized Myasthenia Gravis, highlighting key findings and future directions.

Browse all presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from argenx

View all →

earnings_deck

earnings_deck

Similar presentations from other companies

Browse all →

presentation

Apollo Investment Corporation

presentation

Aqua Metals